NCT05941715View on ClinicalTrials.gov

Faricimab for High-frequent Aflibercept Treated Neovascular Age-related Macular Degeneration

PHASE4CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

July 4, 2023

Primary Completion Date

September 25, 2024

Study Completion Date

February 26, 2025

Conditions
Neovascular Age-related Macular Degeneration
Interventions
DRUG

Aflibercept 40 MG/ML

treat-and-extend

DRUG

Faricimab 120 MG/ML

treat-and-extend

Trial Locations (1)

8036

Department of Ophthalmolgy, Medical University Graz, Graz

All Listed Sponsors
lead

Medical University of Graz

OTHER